Phenotypic characteristics of COPD patients with a smoking history in POPE-study in the Russian Federation

Chronic obstructive pulmonary disease is a significant problem for Russian healthcare. The identification of different clinical phenotypes of the disease may allow individualizing approaches to the treatment of patients with this pathology, while there is insufficient data on the phenotypic characteristics of patients with COPD in Eastern and Central Europe. Methods. The article presents data from 356 outpatient patients with COPD with a smoking history of more than 10 pack/years, who were included in the study randomly without prior selection or invitation. 57.6% of persons were patients without frequent exacerbations. Patients with frequent exacerbations were 33.7% (without the presence of chronic bronchitis – 9.3% and with the presence of chronic bronchitis – 24.4%). An overlap of bronchial asthma and COPD was revealed in 8.7% of the included patients. According to the GOLD (2011), 7% of patients belong to group A, 26.4% to group B, 4.2% to group C, and 63.4% to group D. Results. This paper presents the results of the Russian part of the international POPE-study (Phenotypes of COPD in Central and Eastern Europe), which contains data on COPD clinical phenotypes in Russian patients with a verified diagnosis of COPD. A detailed description of spirometric data, comorbid pathology, and prescribed medications depending on clinical phenotypes is given. A high level of administration of inhaled glucocorticosteroids was revealed, which even patients without frequent exacerbations received in 54% of cases. Conclusion. The obtained data will help to develop optimal approaches to eliminate discrepancies between clinical recommendations for managing patients with COPD and actual clinical practice in Russia.

chronic obstructive pulmonary disease, phenotypes, treatment, comorbid diseases, clinical practice

1. Global Initiative for Chronic Obstructive Lung Disease. 2020 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available at: https://goldcopd.org/gold-reports/

2. Jones P.W. Health status and the spiral of decline. J. COPD. 2009. 6 (1): 59–63. DOI: 10.1080/15412550802587943.

3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease. 2011 Report. Available at: http://www.goldcopd.org/

4. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604. DOI: 10.1164/rccm.200912-1843CC.

5. Koblizek V., Chlumsky J., Zindr V. et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2013; 157 (2): 189–201. DOI: 10.5507/bp.2013.039.

6. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Russian Respiratory Society. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pul'monologiya. 2014; (3): 15–54. DOI: 10.18093/0869-0189-2014-0-3-15-54 (in Russian).

7. Zbozinkova Z., Barczyk A., Tkacova R. et al. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 611–622. DOI: 10.2147/COPD.S88846.

8. Miravitlles M., Soler-Cataluña J.J., Calle M. et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch. Bronconeumol. 2014; 50 (Suppl. 1): 1–16. DOI: 10.1016/S0300-2896(14)70070-5.

9. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 1987; 40 (5): 373–383. DOI: 10.1016/0021-9681(87)90171-8.

10. Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338. DOI: 10.1183/09031936.05.00034805.

11. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26 (5): 948–968. DOI: 10.1183/09031936.05.00035205.

12. Roca J., Burgos F., Sunyer J. et al. References values for forced spirometry. Group of the European Community Respiratory Health Survey. Eur. Respir. J. 1998; 11 (6): 1354–1362. DOI: 10.1183/09031936.98.11061354.

13. Diab N., Gershon A.S., Sin D.D. et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018; 198 (9): 1130–1139. DOI: 10.1164/rccm.201804-0621CI.

14. Miravitlles M., Vogelmeier C., Roche N. et al. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016; 47 (2): 625–637. DOI: 10.1183/13993003.01170-2015.

15. Burrows B., Hopkins J., Fletcher C.M. et al. The emphysematous and bronchial types of chronic airways obstruction: A clinicopathological study of patients in London and Chicago. Lancet. 1966; 287 (7442): 830–835. DOI: 10.1016/s0140-6736(66)90181-4.

16. Cosio B.G., Soriano J.B., López-Campos J.L. et al. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS One. 2016; (11): e0160770. DOI: 10.1371/journal.pone.0160770.

17. Koblizek V., Milenkovic B., Barczyk A. et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur. Respir. J. 2017; 49 (5): 1601446. DOI: 10.1183/13993003.01446-2016.

18. Pasquale M.K., Sun S.X., Song F. et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 757–764. DOI: 10.2147/COPD.S36997.

19. Lindberg A., Sawalha S., Hedman L. et al. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir. Med. 2015; 109 (1): 88–95. DOI: 10.1016/j.rmed.2014.12.001.

20. Martinez F.J., Calverley P.M., Goehring U.M. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentrer randomized controlled trial. Lancet. 2015; 385 (9971): 857–866. DOI: 10.1016/S0140-6736(14)62410-7.

21. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 11531162. DOI: 10.1016/j.rmed.2014.05.013.

22. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2016 Update. Available at: https://ginasthma.org/wp-content/uploads/2016/04/GINA2016-main-report_tracked.pdf [Accessed: May 26, 2016].

23. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017 Report. Available at: http://goldcopd.org [Accessed: January 8, 2017].

24. Tudoric N., Koblizek V., Miravitlles M. et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur. Respir. J. 2017; 49 (4): 1602518. DOI: 10.1183/13993003.02518-2016.